Another study showed that histone deacetylase 3 (HDAC3) inhibitor upregulates PD-L1 expression through epigenetic mechanisms on DCs in the TME in B-cell lymphomas [86]. Here, HDAC3 is linked to B-cell non-Hodgkin lymphoma.